- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03267147
PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS (PANORA)
March 1, 2022 updated by: Dr. Frank Behrens, Fraunhofer Institute for Molecular Biology and Applied Ecology
PREVALENCE OF ANTI-CYCLIC CITRULLINATED PEPTIDE (Anti-CCP) POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS POSSIBLY RELATED TO EARLY RHEUMATOID ARTHRITIS IN GENERAL PRACTICES IN GERMANY
Non-interventional, prospective, observational study to assess the relative risk of anti-CCP positive patients to develop (subclinical) signs of inflammation in accordance with early Rheumatoid Arthritis (RA) in a population without pre-classified RA but new1 onset of non-specific musculoskeletal (MSK) symptoms in general practices in Germany and subsequent 36 months follow-up by rheumatologists
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Studies of early arthritis cohorts have shown that a large number of early arthritis patients cannot be accurately diagnosed at their first visit, and hence are often referred as undifferentiated arthritis patients.
If patients are found to be anti-CCP(+) when referred to the clinician, however, more than 90% develop RA within 3 years - in contrast to only 30% of the anti-CCP(-) patients.
The presence of anti-CCP antibodies in undifferentiated arthritis therefore accurately predicts development of RA.
Anti-CCP antibodies are very specific for RA, and they are produced at significant level very early in disease.
The specificity of anti-CCP antibodies for the diagnosis of RA is high (94.1-99.0%).
Moreover, it has been reported that anti-CCP antibodies can be present many years before the first visit to the clinic (up to 18 years).
Furthermore, the presence of anti-CCP antibodies at the first visit to the clinician predicts radiographic progression, as demonstrated by many studies that have shown a strong association of anti-CCP positivity with the development of bone erosions.Early diagnosis of RA coupled with rational use of disease-modifying anti-rheumatic drugs (DMARD) has been shown to have a favourable effect on the course of the disease.
Early and accurate diagnosis has therefore become increasingly important.
Implementing anti-CCP quick tests in general practices could facilitate an early detection of RA or the allocation to a high risk RA group.
This, in turn, would guarantee an early referral of the patient to a rheumatologist and together with other clinical examinations can aid in the early diagnosis and treatment.
As has been shown in many studies an early intervention is vital to preserve joint function and to improve patient care.
In this study, we want to assess the relative risk for patients derived from GPs in Germany with new onset of non-specific MSK symptoms and anti-CCP test positivity to develop (subclinical) signs of inflammation in accordance with early RA.
Those patients will be identified in general practices and will be tested for anti-CCP status.
Anti-CCP positive patients will then be introduced to a rheumatologist to validate anti-CCP status and examine presence of clinical signs of early RA in addition to subclinical signs of MSK inflammation.
Furthermore, to focus on the possibility of early detection of anti-CCP before the onset of clinically active arthritis, patients will be followed-up by a rheumatologist until detection of early RA or up to 36 months in total.
Early RA will be examined using standard of care for signs of inflammation including clinical examination for swollen and tender joints.
In addition, ultrasound will be performed to assess joint inflammation as well as fluorescence optical imaging technique (Xiralite®) to sensitively illustrate changes in microvascularisation as a marker of subclinical inflammation.
In cases of RA diagnosis, the study ends with the date of diagnosis and patients will receive treatment according to local guidelines earlier and medical care will be continued in clinical routine care conditions outside of the study.
Moreover, the cooperation status between GPs and rheumatologists will be evaluated using qualitative interviews.
Feasibility of the diagnosis of early RA in at risk patients as well as the feasibility of the transferral of these patients from the general practice to the rheumatologist will be assessed.
Training of GPs for detection of early RA will be improved.
Overall, the hypothesis of the study is that patients with new onset of unspecific MSK-symptoms and who are positive for anti-CCP, which both are risk factors for developing RA, will be earlier introduced to and monitored by a rheumatologist for proper clinical examination and potential treatment when establishing RA, which in turn will not only improve patient care, disease outcomes and quality of life, but might also be cost effective.
Study Type
Observational
Enrollment (Actual)
986
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hessia
-
Frankfurt am Main, Hessia, Germany, 60596
- CIRI
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
population without pre-classified RA but new onset of non-specific musculoskeletal (MSK) symptoms
Description
Inclusion Criteria:
- New onset of non-specific MSK symptoms, including, but not limited to, arthralgia of the hands and the large joints such as wrists, knees, and shoulders
- Written informed consent obtained prior to the initiation of any study protocol-required procedures
- General understanding of study procedure and informed consent
- Age ≥ 18 and ≤ 65 years
Exclusion Criteria:
- RA diagnosed according to modified EULAR/ACR (american college of rheumatology)-criteria
- Other known arthritis
- Other known reasons for MSK symptoms, e.g. mechanical, traumatic, etc.
- MSK symptoms previously reported at another (general) practice
- Alcohol, drug or chemical abuse
- Underage or incapable patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
antiCCP positive
Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis no intervention is given |
no intervention is given
|
antiCCP negative
Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
|
no intervention is given
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the relative risk in patients with new onset of non-specific MSK symptoms who are anti-CCP positive to develop (subclinical) signs of inflammation in accordance with early RA in general practices in Germany
Time Frame: every 6 months up to 3 years
|
Determination if RA symptoms are present
|
every 6 months up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
diagnosis of RA in the group of anti-CCP positive patients with new onset of non-specific MSK symptoms
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
subclinical signs of inflammation using routine examination methods in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
subclinical signs of inflammation using fluorescence optical imaging technique in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
subclinical signs of inflammation using ultrasound in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
anti-CCP level over time in anti-CCP positive patients
Time Frame: over 3 years
|
over 3 years
|
|
EQ5D
Time Frame: every 6 months up to 3 years
|
Questionnaire to assess Quality of Life profile of anti-CCP positive patients
|
every 6 months up to 3 years
|
SF36
Time Frame: every 6 months up to 3 years
|
Questionnaire to assess Quality of Life profile of anti-CCP positive patients
|
every 6 months up to 3 years
|
HAQ
Time Frame: every 6 months up to 3 years
|
Questionnaire to assess disability profile of anti-CCP positive patients
|
every 6 months up to 3 years
|
PHQ-9
Time Frame: every 6 months up to 3 years
|
Questionnaire to assess depression profile of anti-CCP positive patients
|
every 6 months up to 3 years
|
WPAI
Time Frame: every 6 months up to 3 years
|
Questionnaire to assess work ability profile of anti-CCP positive patients
|
every 6 months up to 3 years
|
assessment of time to disease in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment of correlation of anti-CCP level in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment quality of life (QoL) in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment work ability profile in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment subclinical signs of inflammation in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment risk of depression in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
assessment of grade of disability in anti-CCP positive patients
Time Frame: every 6 months up to 3 years
|
every 6 months up to 3 years
|
|
diagnosis of RA in the group of ELISA test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time Frame: 1 year
|
1 year
|
|
diagnosis of RA in the group of ELISA test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time Frame: 3 years
|
3 years
|
|
diagnosis of RA in the group of quick test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time Frame: 1 year
|
1 year
|
|
Qualitative assessment of general practitioners' (GP) routine care
Time Frame: 1 year
|
qualitative interviews with the GP to evaluate current status of how patients with MSK symptoms are treated/forwarded in general practices
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Frank Behrens, MD, Fraunhofer IME
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
April 27, 2017
Primary Completion (ACTUAL)
December 16, 2021
Study Completion (ACTUAL)
February 15, 2022
Study Registration Dates
First Submitted
July 4, 2017
First Submitted That Met QC Criteria
August 28, 2017
First Posted (ACTUAL)
August 30, 2017
Study Record Updates
Last Update Posted (ACTUAL)
March 2, 2022
Last Update Submitted That Met QC Criteria
March 1, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMP-1016_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on no intervention is given
-
University of Dublin, Trinity CollegeCompleted
-
University College, LondonUnknownDiabetes MellitusUnited Kingdom
-
Nelson ClaureCompletedIntraventricular Hemorrhage | Intracranial Hemorrhage | Cerebral HypoxiaUnited States
-
UConn HealthRecruitingMyocardial Infarction | Ischemia | Stroke, IschemicUnited States
-
King's College LondonCompleted
-
Novo Nordisk A/SCompletedObesity | OverweightUnited Arab Emirates
-
Novo Nordisk A/SRecruitingIdiopathic Short StatureUnited States
-
FrieslandCampinaEnrolling by invitation
-
University of LeicesterNot yet recruiting